CJC-1295 and Ipamorelin are two peptides that work together to stimulate the release of growth hormone from the pituitary gland. The combination is popular among bodybuilders, athletes and researchers who want a more consistent and prolonged growth-hormone surge without the side effects that can accompany other stimulants. This guide explains what each peptide does, how they interact when combined, the best dosing protocols for beginners and experienced users alike, and practical tips for storing, preparing and tracking results.
What is CJC-1295/Ipamorelin? A Researcher’s Guide to This Peptide Combination
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). In its most common form it carries a "no DAC" (depot-antibody-binding) modification, which means it has a relatively short half-life of about one hour. When injected it quickly raises circulating levels of growth hormone and, indirectly, insulin-like growth factor-1 (IGF-1). Ipamorelin is a hexapeptide that mimics ghrelin’s action on the growth-hormone secretagogue receptor. It is highly selective for the growth-hormone pathway and has minimal effects on cortisol or prolactin, making it ideal for use in combination with CJC-1295.
The pairing of CJC-1295 (no DAC) and Ipamorelin delivers a double stimulus: CJC-1295 primes the pituitary to respond to the secretagogue signal from Ipamorelin. The result is a more robust, sustained release of growth hormone than either peptide alone. Research shows that the combination can increase IGF-1 levels by up to 300 % over baseline while keeping side effects low.
Understanding CJC-1295 (No DAC)
The "no DAC" version of CJC-1295 has a short biological half-life, so its action peaks quickly and then falls off within a few hours. This makes it suitable for use in a once-daily or twice-daily regimen that mimics the natural circadian rhythm of growth hormone secretion. Because the peptide is cleared rapidly, users can avoid the prolonged suppression of other hormones that sometimes occurs with longer-acting forms.
Key pharmacokinetic points:
Peak serum concentration occurs about 30–60 minutes after injection. The effect lasts roughly 4–6 hours before levels drop toward baseline. When combined with Ipamorelin, the peak IGF-1 response is delayed by 2–3 hours relative to CJC-1295 alone, giving a smoother overall profile.
Typical dosing for the no DAC form starts at 100–200 µg per injection. Most protocols use two injections per day – one before bed and one in the early morning – to align with natural growth-hormone peaks. Some users add a third dose mid-morning if they are training heavily or want an extra anabolic push.
Ipamorelin dosing usually ranges from 100–300 µg per injection, given at the same times as CJC-1295 for synergy. The combination is often prepared in a single vial with a sterile diluent, then split into aliquots for each injection.
Practical dosing guidelines
Start low and go slow – For beginners, begin with 100 µg of CJC-1295 and 150 µg of Ipamorelin twice daily (morning and bedtime).
Track responses – Record IGF-1 levels, body composition changes, sleep quality, and any side effects each week.
Increase gradually – After 4–6 weeks, if you see stable gains and no adverse effects, add 50 µg to each injection until you reach the upper limit of 200 µg CJC-1295 / 300 µg Ipamorelin.
Cycle length – A typical cycle lasts 8–12 weeks, followed by a break of at least 4 weeks before restarting.
Storage and handling tips
Keep the peptides in the refrigerator (2–8 °C).
Use sterile syringes and needles; never share equipment.
Dilute with bacteriostatic water or normal saline to a concentration that allows accurate dosing (e.g., 1 mg/mL).
Label each vial with the date of preparation and expiration.
Monitoring safety
While CJC-1295/Ipamorelin is generally well tolerated, users should watch for:
Water retention or bloating – common in the first week. Increased appetite – a natural consequence of ghrelin mimetic activity. Joint pain – rare but possible if IGF-1 rises too quickly.
Regular blood work (IGF-1, thyroid function, fasting glucose) helps ensure that hormone levels remain within safe ranges.
Related posts
For further reading on peptide protocols and safety considerations, check out these related discussions:
"Comparing GHRP-6 to Ipamorelin: Which Secretagogue Is Better?"
"The Role of a No DAC CJC-1295 in Muscle Recovery."
"Combining Peptides with Resistance Training: Optimizing Timing for Maximal Gains."
These resources expand on the mechanics behind each peptide, offer alternative dosing schedules, and provide user testimonials that illustrate how the combination can fit into different training programs.
